{"filing":{"accession_number":"0001493152-26-029736","cik":"0001873093","ticker":"GDTC","company_name":"CytoMed Therapeutics Ltd","form":"6-K","filing_date":"2026-06-23","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1873093/000149315226029736/form6-k.htm"},"events":[{"id":13087,"run_id":11614,"accession_number":"0001493152-26-029736","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The 6-K discloses two related transactions by Chairman Choo Chee Kong: (1) an offer to acquire up to 200,000 Company shares from independent shareholders via private purchase agreement, and (2) a S$300,000 investment by his wholly-owned EP Capital Inc. into LongevityBank (a Company subsidiary), increasing EP Capital's stake from 6.4% to 12.0%. While these transactions involve significant capital deployment and potential changes to shareholding structure and subsidiary ownership, they do not fit neatly into standard event categories—they are neither a formal M\u0026A transaction (no merger or acquisition of the Company itself), nor a simple insider share purchase, nor a capital raise by the Company. The disclosure is material because it signals insider confidence and capital commitment, but the event's nature—insider accumulation and subsidiary investment—is ambiguous enough to warrant the catch-all category.","company_name":"CytoMed Therapeutics Ltd","ticker":"GDTC","filing_date":"2026-06-23","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":10131,"accession_number":"0001493152-26-029736","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The 6-K discloses two related transactions by Chairman Choo Chee Kong: (1) an offer to acquire up to 200,000 Company shares from independent shareholders via private purchase agreement, and (2) a S$300,000 investment by his wholly-owned EP Capital Inc. into LongevityBank (a Company subsidiary), increasing EP Capital's stake from 6.4% to 12.0%. While these transactions involve significant capital deployment and potential changes to shareholding structure and subsidiary ownership, they do not fit neatly into standard event categories—they are neither a formal M\u0026A transaction (no merger or acquisition of the Company itself), nor a simple insider share purchase, nor a capital raise by the Company. The disclosure is material because it signals insider confidence and capital commitment, but the event's nature—insider accumulation and subsidiary investment—is ambiguous enough to warrant the catch-all category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T16:14:47.995275+00:00","company_name":"CytoMed Therapeutics Ltd","ticker":"GDTC","filing_date":"2026-06-23"}]}